Company intelligence / Profile preview

Euphrates Vascular

St. Louis/Saint Louis, Missouri, United Stateseuphratesvascular.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Euphrates Vascular has developed the Pulse NanoMED™/Pulse MED™ System, a first-of-kind nanotechnology-based interventional device using iron oxide nanoparticles guided by external magnetic fields to treat distal vessel occlusions that are unreachable with current wires/catheters. Early preclinical and initial clinical data suggest faster and more comprehensive reperfusion in acute ischemic stroke and peripheral vascular disease compared to standard approaches. The system aims to improve outcomes by delivering clot-busting drugs like tPA more efficiently into blocked vessels.

Therapeutic areas: DermatologyCardiovascularNeurology
Modalities: DeviceNanoparticleNanotechnology drug delivery platform
Industry: Therapeutic Medical Devices

Partnerships

NIH awards/grants

Beyond the preview

Go deeper on Euphrates Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Euphrates Vascular.

Explore the full profile